Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Passage Bio (NASDAQ: PASG) is a genetics medicine company founded in 2017 and headquartered in Philadelphia, Pennsylvania. The company specializes in developing therapeutics for disorders of the central nervous system, with a primary focus on gene therapy. Operating within the biotechnology and pharmaceutical industry, Passage Bio caters to the healthcare sector, particularly those dealing with neurological disorders.
Since its inception, Passage Bio has made significant strides in the field of gene therapy, raising a total of $225.5 million in funding. This substantial investment demonstrates the confidence that investors have in the company's potential and its innovative approach to treating central nervous system disorders.
As a publicly traded company on the NASDAQ under the ticker symbol PASG, Passage Bio has already completed its initial public offering (IPO). Investors interested in buying Passage Bio stock or shares can do so through established stock exchanges. However, it's important to note that as with any investment, thorough research and consideration of market conditions are essential before making investment decisions.
While we don't have specific information about future IPO prospects for Passage Bio, given that it's already a public company, investors and market watchers may be interested in following the company's financial performance, clinical trial results, and any potential secondary offerings or other significant corporate events that could impact its stock value.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Passage Bio's IPO prospects remain uncertain, investors interested in the biotechnology sector don't have to wait on the sidelines. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the biotech industry. Our platform allows you to diversify your portfolio with lower minimum investments in emerging companies like Passage Bio, potentially benefiting from their growth before they go public. Explore opportunities in innovative healthcare and gene therapy companies through Linqto's user-friendly interface.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
